Up to 50% of patients treated with intravesical agents for superficial bladder cancer will experience recurrence. Response rates to second-line intravesical therapies range from 20% to 40%. For these ...
There are few well-performed studies that specifically address adherence to recent bladder cancer guidelines. Schrag et al. evaluated adherence to cystoscopic surveillance following the diagnosis of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback